|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We previously reported that ILK functions as either a tumor suppressor or an oncogene in rhabdomyosarcoma (RMS), in a manner linked to expression of the c-jun amino terminal kinase-1 (JNK1).
|
20495362 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, this study demonstrates that Wnt-7a and Fzd-9 signaling through activation of the JNK pathway induces cadherin proteins and the receptor tyrosine kinase inhibitor Sprouty-4 and represents a novel tumor suppressor pathway in lung cancer that is required for maintenance of epithelial differentiation and inhibition of transformed cell growth in a subset of human NSCLCs.
|
15705594 |
2005 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Together, our findings provide a novel mechanism of tumor growth that acts through intracellular Ca<sup>2+</sup> levels to modulate JNK-mediated Hippo signaling.
|
31649333 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Loss of scrib promotes cooperation with Abrupt through impaired Hippo signalling, which is required and sufficient for cooperative overgrowth with Abrupt, and JNK (Jun kinase) signalling, which is required for tumour cell migration/invasion but not overgrowth.
|
23874226 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo, potentiation of bevacizumab, oxaliplatin, and the combination by JNK inhibition was confirmed in HT29-derived mouse xenografts, in which tumor growth delay was greater in the presence of CC-401.
|
26023085 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This enhancement in JNK1 activation is associated with an increased tumor size and a lack of encapsulation of the tumors.
|
19041150 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Taken together we show that Ets21C is a crucial player in regulating the transcriptional program of the JNK pathway and enhances our understanding of the mechanisms that govern neoplastic growth.
|
27713480 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our findings demonstrate that the pretreatment of tumor cells with IFN-γ enhances B7-DC expression through ERK and JNK pathways.
|
20390427 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of regucalcin was found to suppress signaling pathways including Akt, MAP kinase and SAPK/JNK, to increase the protein levels of p53, a tumor suppresser, and to decrease K-ras, c-fos and c-jun, a oncogene, by suppressing signaling pathways that are related to signaling of K-ras.
|
26935290 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that TNF-alpha, via NF-kappaB, and JNK induces MIF and EMMPRIN in macrophage to tumor cell cocultures and this leads to increased invasive capacity of the tumor cells.
|
16002723 |
2005 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DUSP4 (MKP-2), a member of the mitogen-activated protein kinase phosphatase (MKP) family and potential tumor suppressor, negatively regulates the MAPKs (mitogen-activated protein kinases) ERK, p38 and JNK.
|
22965873 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Diallyl trisulfide suppresses tumor growth through the attenuation of Nrf2/Akt and activation of p38/JNK and potentiates cisplatin efficacy in gastric cancer treatment.
|
28344324 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, restoration of JNK1 in ARMS reestablished a tumor-suppressive function for ILK.
|
19478459 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results highlight the functional significance of the JNK pathway in epithelial cells with defective cytokinesis and elucidate a mechanism used by emerging tumor cells to bypass this tumor-suppressive barrier and develop into tumors.
|
29719260 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Ex vivo tumor analysis indicated significant molecular activity such as changes in the level of phosphoproteins JNK, Akt, and inflammation markers IL-6 and IFN-γ.
|
28135100 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A JNK1 inhibitor also increased the latency period and decreased growth of MMTV-neu tumors by induction of apoptosis.
|
20944115 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of p-JNK1 in tumor tissue was an independent predictor of peritoneal metastasis (OR 4.01, 95 % CI 1.32-12.17).
|
24395444 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Matrine promoted the expression of GADD45B, a tumor suppressive gene that is involved in the regulation of cell cycle, DNA damage repair, cell survival, aging, apoptosis and other cellular processes through p38/JNK, ROS-GADD45B-p38, or other signal pathways.
|
29356020 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
|
26637668 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Combining <i>in vitro</i> and <i>in vivo</i> functional analyses, we demonstrate that JNK inhibition both promotes tumor cell cytostasis and blocks activation of the proapoptotic protein Bax, thereby antagonizing chemotherapy-mediated cytotoxicity.
|
28611109 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Decreased p-JNK1/2 expression in cancer tissues was observed in 48.5% of breast infiltrating ductal carcinoma (IDC) cases and was correlated significantly with the increased tumor grade and the decreased age at diagnosis (p = 0.030 and 0.029).
|
16381010 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, A549 cells either pre-treated with SP600125 or transiently transfected with siRNAs against the JNK genes in vitro showed substantially reduced ability to initiate tumor formation upon implantation into nude mice, implying that the cell intrinsic JNK activity of A549 cells is essential for the maintenance of their tumor-initiating capacity.
|
23912840 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Liver-specific JNK1/2 deletion led to tumor reduction and enhanced survival in Akt/Notch- or p53/Kras-induced ICC models.
|
28609656 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, the vast majority of protein changes mapped to six cellular networks, which included known oncogenes (JNK, c-myc, and N-myc) and tumor suppressor genes (p53 and transforming growth factor-β) as critical components.
|
21136598 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
c-Jun N-terminal kinase in pancreatic tumor stroma augments tumor development in mice.
|
28837246 |
2017 |